{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T16:56:01Z","timestamp":1792342561212,"version":"4.4.0"},"reference-count":97,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T00:00:00Z","timestamp":1636329600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["19PRE34460013"],"award-info":[{"award-number":["19PRE34460013"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK103047"],"award-info":[{"award-number":["DK103047"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R35GM131839"],"award-info":[{"award-number":["R35GM131839"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["S10OD020012"],"award-info":[{"award-number":["S10OD020012"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ymthe.2021.11.007","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T02:01:56Z","timestamp":1636596116000},"page":"1329-1342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["An RNAi therapeutic targeting hepatic DGAT2 in a genetically obese mouse model of nonalcoholic steatohepatitis"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8798-3676","authenticated-orcid":false,"given":"Batuhan","family":"Yenilmez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3400-5873","authenticated-orcid":false,"given":"Nicole","family":"Wetoska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9018-594X","authenticated-orcid":false,"given":"Mark","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimas","family":"Echeverria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2546-0236","authenticated-orcid":false,"given":"Kyounghee","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Lifshitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia F.","family":"Alterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7897-6503","authenticated-orcid":false,"given":"Matthew R.","family":"Hassler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6633-3495","authenticated-orcid":false,"given":"Samuel","family":"Hildebrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"DiMarzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"McHugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1279-2995","authenticated-orcid":false,"given":"Lorenc","family":"Vangjeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacquelyn","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meixia","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianlin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6813-3262","authenticated-orcid":false,"given":"Michael A.","family":"Brehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6928-8071","authenticated-orcid":false,"given":"Anastasia","family":"Khvorova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4075-7350","authenticated-orcid":false,"given":"Michael P.","family":"Czech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2021.11.007_bib1","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/hep.28785","article-title":"The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2021.11.007_bib2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2021.11.007_bib3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12916-019-1321-x","article-title":"Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts","volume":"17","author":"Alexander","year":"2019","journal-title":"BMC Med."},{"key":"10.1016\/j.ymthe.2021.11.007_bib4","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/hep.25539","article-title":"Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease","volume":"55","author":"Lomonaco","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2021.11.007_bib5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2021.11.007_bib6","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMra1503519","article-title":"Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis","volume":"377","author":"Diehl","year":"2017","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ymthe.2021.11.007_bib7","first-page":"24 908","article-title":"Mechanisms of NAFLD development and therapeutic strategies","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2021.11.007_bib8","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2021.11.007_bib9","doi-asserted-by":"crossref","first-page":"e1001324","DOI":"10.1371\/journal.pgen.1001324","article-title":"Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits","volume":"7","author":"Speliotes","year":"2011","journal-title":"PLoS Genet."},{"key":"10.1016\/j.ymthe.2021.11.007_bib10","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/hep.23622","article-title":"Homozygosity for the patatin-like phospholipase-3\/adiponutrin i148m polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease","volume":"51","author":"Valenti","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2021.11.007_bib11","first-page":"1","article-title":"TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease","volume":"5","author":"Liu","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2021.11.007_bib12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.21037\/tgh.2019.06.06","article-title":"Emerging medical therapies for non-alcoholic fatty liver disease and for alcoholic hepatitis","volume":"4","author":"Wong","year":"2019","journal-title":"Translational Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymthe.2021.11.007_bib13","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/hep.27999","article-title":"Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: a systematic review and network meta-analysis","volume":"62","author":"Singh","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2021.11.007_bib14","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00125-011-2446-4","article-title":"Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials","volume":"55","author":"Musso","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.ymthe.2021.11.007_bib15","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.jhep.2011.03.016","article-title":"The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis","volume":"55","author":"Mahady","year":"2011","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ymthe.2021.11.007_bib16","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1210\/jc.2014-3794","article-title":"Effect of vildagliptin on hepatic steatosis","volume":"100","author":"Macauley","year":"2015","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ymthe.2021.11.007_bib17","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jhep.2016.04.021","article-title":"Sitagliptin vs. placebo for non-alcoholic fatty liver disease: a randomized controlled trial","volume":"65","author":"Cui","year":"2016","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ymthe.2021.11.007_bib18","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ymthe.2021.11.007_bib19","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2021.11.007_bib20","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/liv.14209","article-title":"CONTROL: a randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients","volume":"39","author":"Pockros","year":"2019","journal-title":"Liver Int."},{"key":"10.1016\/j.ymthe.2021.11.007_bib21","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2021.11.007_bib22","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jhep.2019.10.023","article-title":"Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase IIb study","volume":"72","author":"Harrison","year":"2020","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ymthe.2021.11.007_bib23","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/hep.29477","article-title":"A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","volume":"67","author":"Friedman","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2021.11.007_bib24","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/hep.31108","article-title":"Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study","volume":"72","author":"Ratziu","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2021.11.007_bib25","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials","volume":"73","author":"Harrison","year":"2020","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ymthe.2021.11.007_bib26","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.cgh.2018.04.042","article-title":"Acetyl-CoA carboxylase inhibitor GS-0976 for 12\u00a0weeks reduces hepatic de novo lipogenesis and steatosis in patients with nonalcoholic steatohepatitis","volume":"16","author":"Lawitz","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymthe.2021.11.007_bib27","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1053\/j.gastro.2018.07.027","article-title":"GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease","volume":"155","author":"Loomba","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ymthe.2021.11.007_bib28","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1002\/hep.30097","article-title":"Acetyl-CoA carboxylase inhibition reverses NAFLD and\u00a0hepatic insulin resistance but promotes hypertriglyceridemia in rodents","volume":"68","author":"Goedeke","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2021.11.007_bib29","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.cmet.2017.07.009","article-title":"Acetyl CoA carboxylase inhibition reduces hepatic steatosis but elevates plasma triglycerides in mice and humans: a bedside to bench investigation","volume":"26","author":"Kim","year":"2017","journal-title":"Cell Metab."},{"key":"10.1016\/j.ymthe.2021.11.007_bib30","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2018.07.006","article-title":"Simtuzumab is ineffective for patients with bridging\u00a0fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis","volume":"155","author":"Harrison","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ymthe.2021.11.007_bib31","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jhep.2019.11.024","article-title":"A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis","volume":"72","author":"Harrison","year":"2020","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ymthe.2021.11.007_bib32","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jhep.2019.12.010","article-title":"Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension","volume":"72","author":"Garcia-Tsao","year":"2020","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ymthe.2021.11.007_bib33","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/liv.14355","article-title":"Current management of non-alcoholic steatohepatitis","volume":"40","author":"Muthiah","year":"2020","journal-title":"Liver Int."},{"key":"10.1016\/j.ymthe.2021.11.007_bib34","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1056\/NEJMp1101548","article-title":"Development of novel combination therapies","volume":"364","author":"Woodcock","year":"2011","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ymthe.2021.11.007_bib35","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1194\/jlr.R800018-JLR200","article-title":"DGAT enzymes and triacylglycerol biosynthesis","volume":"49","author":"Yen","year":"2008","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.ymthe.2021.11.007_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20121689","article-title":"Hepatic triacylglycerol synthesis and secretion: DGAT2 as the link between glycaemia and triglyceridaemia","volume":"451","author":"Zammit","year":"2013","journal-title":"Biochem. J."},{"key":"10.1016\/j.ymthe.2021.11.007_bib37","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/hep.20783","article-title":"Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice","volume":"42","author":"Yu","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2021.11.007_bib38","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/hep.21655","article-title":"Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis","volume":"45","author":"Yamaguchi","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2021.11.007_bib39","doi-asserted-by":"crossref","first-page":"22678","DOI":"10.1074\/jbc.M704213200","article-title":"Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance","volume":"282","author":"Choi","year":"2007","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2021.11.007_bib40","doi-asserted-by":"crossref","first-page":"9701","DOI":"10.1126\/scitranslmed.aav9701","article-title":"Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis","volume":"11","author":"Amin","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2021.11.007_bib41","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2468-1253(20)30186-2","article-title":"Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial","volume":"5","author":"Loomba","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymthe.2021.11.007_bib42","first-page":"35 238","article-title":"The chemical evolution of oligonucleotide therapies of clinical utility","author":"Khvorova","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2021.11.007_bib43","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2021.11.007_bib44","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/nsb0901-746","article-title":"RNA interference: listening to the sound of silence","volume":"8","author":"Zamore","year":"2001","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.ymthe.2021.11.007_bib45","series-title":"Modified RNAI Agents","author":"Rajeev","year":"2013"},{"key":"10.1016\/j.ymthe.2021.11.007_bib46","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ymthe.2021.11.007_bib47","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1208760","article-title":"Safety and efficacy of RNAi therapy for transthyretin amyloidosis","volume":"369","author":"Coelho","year":"2013","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ymthe.2021.11.007_bib48","first-page":"28 109","article-title":"GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics","author":"Springer","year":"2018","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ymthe.2021.11.007_bib49","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing","volume":"136","author":"Nair","year":"2014","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ymthe.2021.11.007_bib50","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/cbic.201600130","article-title":"5\u2032-(E)-vinylphosphonate: a stable phosphate mimic can improve the RNAi activity of siRNA-GalNAc conjugates","volume":"17","author":"Parmar","year":"2016","journal-title":"ChemBioChem"},{"key":"10.1016\/j.ymthe.2021.11.007_bib51","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ymthe.2016.10.019","article-title":"Clinical proof of concept for a novel hepatocyte-targeting GalNAc-siRNA conjugate","volume":"25","author":"Zimmermann","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2021.11.007_bib52","doi-asserted-by":"crossref","first-page":"10969","DOI":"10.1093\/nar\/gkx818","article-title":"Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates","volume":"45","author":"Nair","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2021.11.007_bib53","doi-asserted-by":"crossref","first-page":"8537","DOI":"10.1021\/jacs.7b02694","article-title":"Chirality dependent potency enhancement and structural impact of glycol nucleic acid modification on siRNA","volume":"139","author":"Schlegel","year":"2017","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ymthe.2021.11.007_bib54","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1093\/nar\/gky037","article-title":"Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in\u00a0vivo","volume":"46","author":"Hassler","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2021.11.007_bib55","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1038\/mtna.2016.50","article-title":"Docosahexaenoic acid conjugation enhances distribution and safety of siRNA upon local administration in mouse brain","volume":"5","author":"Nikan","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2021.11.007_bib56","doi-asserted-by":"crossref","first-page":"7581","DOI":"10.1093\/nar\/gkx507","article-title":"5\u2019-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in\u00a0vivo","volume":"45","author":"Haraszti","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2021.11.007_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-02989-4","article-title":"Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity","volume":"9","author":"Janas","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2021.11.007_bib58","doi-asserted-by":"crossref","first-page":"e266","DOI":"10.1038\/mtna.2015.38","article-title":"Hydrophobically modified siRNAs silence huntingtin mRNA in primary neurons and mouse brain","volume":"4","author":"Alterman","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2021.11.007_bib59","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.ebiom.2019.04.054","article-title":"Early blood-brain barrier dysfunction predicts neurological outcome following aneurysmal subarachnoid hemorrhage","volume":"43","author":"Choung","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ymthe.2021.11.007_bib60","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.ebiom.2019.04.054","article-title":"Early blood-brain barrier dysfunction predicts neurological outcome following aneurysmal subarachnoid hemorrhage","volume":"43","author":"Wittrup","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ymthe.2021.11.007_bib61","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1093\/nar\/gkg393","article-title":"Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells","volume":"31","author":"Czauderna","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2021.11.007_bib62","series-title":"Modified Double-Stranded RNA Agents","author":"Maier","year":"2016"},{"key":"10.1016\/j.ymthe.2021.11.007_bib63","doi-asserted-by":"crossref","first-page":"7777","DOI":"10.1073\/pnas.1406228111","article-title":"RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice","volume":"111","author":"Yasuda","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.ymthe.2021.11.007_bib64","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(13)61914-5","article-title":"Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial","volume":"383","author":"Fitzgerald","year":"2014","journal-title":"The Lancet"},{"key":"10.1016\/j.ymthe.2021.11.007_bib65","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ymthe.2021.11.007_bib66","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ymthe.2021.11.007_bib67","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis: analysis of the APOLLO study","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2021.11.007_bib68","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.omtn.2016.12.003","article-title":"Preclinical and clinical advances of GalNAc-decorated nucleic acid therapeutics","volume":"6","author":"Huang","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2021.11.007_bib69","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1089\/nat.2015.0578","article-title":"A high-throughput method for direct detection of therapeutic oligonucleotide-induced gene silencing in\u00a0vivo","volume":"26","author":"Coles","year":"2016","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ymthe.2021.11.007_bib70","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1038\/mtna.2016.50","article-title":"Docosahexaenoic acid conjugation enhances distribution and safety of siRNA upon local administration in mouse brain","volume":"5","author":"Nikan","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2021.11.007_bib71","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.30765","article-title":"Hepatocyte deletion of triglyceride-synthesis enzyme acyl CoA: diacylglycerol acyltransferase 2 reduces steatosis without increasing inflammation or fibrosis in mice","volume":"70","author":"Gluchowski","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2021.11.007_bib72","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1016\/j.ymthe.2017.09.020","article-title":"Survival advantage of both human hepatocyte xenografts and genome-edited hepatocytes for treatment of \u03b1-1 antitrypsin deficiency","volume":"25","author":"Borel","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2021.11.007_bib73","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1194\/jlr.M081836","article-title":"Interplay between ChREBP and SREBP-1c coordinates postprandial glycolysis and lipogenesis in livers of mice","volume":"59","author":"Linden","year":"2018","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.ymthe.2021.11.007_bib74","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/hep4.1405","article-title":"A therapeutic silencing RNA targeting hepatocyte TAZ prevents and reverses fibrosis in nonalcoholic steatohepatitis in mice","volume":"3","author":"Wang","year":"2019","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.ymthe.2021.11.007_bib75","doi-asserted-by":"crossref","first-page":"11915","DOI":"10.1073\/pnas.0805434105","article-title":"Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates","volume":"105","author":"Frank-Kamenetsky","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.ymthe.2021.11.007_bib76","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1038\/mtna.2015.36","article-title":"Preclinical development of a subcutaneous ALAS1 RNAi therapeutic for treatment of hepatic porphyrias using circulating RNA quantification","volume":"4","author":"Chan","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2021.11.007_bib77","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1021\/jm049167j","article-title":"Fully 2\u2032-modified oligonucleotide duplexes with improved in\u00a0vitro potency and stability compared to unmodified small interfering RNA","volume":"48","author":"Allerson","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ymthe.2021.11.007_bib78","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.cmet.2018.04.004","article-title":"DGAT2 inhibition alters aspects of triglyceride metabolism in rodents but not in non-human primates","volume":"27","author":"McLaren","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.ymthe.2021.11.007_bib79","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1172\/JCI0215593","article-title":"SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver","volume":"109","author":"Horton","year":"2002","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2021.11.007_bib80","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1073\/pnas.0914798107","article-title":"Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis","volume":"107","author":"Li","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.ymthe.2021.11.007_bib81","doi-asserted-by":"crossref","first-page":"8182","DOI":"10.1073\/pnas.1608987113","article-title":"Insulin induction of SREBP-1c in rodent liver requires LXR\u03b1-c\/EBP\u03b2 complex","volume":"113","author":"Tian","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.ymthe.2021.11.007_bib82","doi-asserted-by":"crossref","first-page":"11041","DOI":"10.1073\/pnas.96.20.11041","article-title":"A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood","volume":"96","author":"Brown","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.ymthe.2021.11.007_bib83","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1152\/ajpendo.00027.2006","article-title":"Deficiency of carbohydrate-activated transcription factor ChREBP prevents obesity and improves plasma glucose control in leptin-deficient (ob\/ob) mice","volume":"291","author":"Iizuka","year":"2006","journal-title":"Am. J. Physiol. - Endocrinol. Metab."},{"key":"10.1016\/j.ymthe.2021.11.007_bib84","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2337\/db06-0200","article-title":"Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob\/ob mice","volume":"55","author":"Dentin","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.ymthe.2021.11.007_bib85","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1210\/en.2012-1725","article-title":"The role of the carbohydrate response element-binding protein in male fructose-fed rats","volume":"154","author":"Erion","year":"2013","journal-title":"Endocrinology"},{"key":"10.1016\/j.ymthe.2021.11.007_bib86","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.cell.2011.09.045","article-title":"A conserved SREBP-1\/phosphatidylcholine feedback circuit regulates lipogenesis in metazoans","volume":"147","author":"Walker","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2021.11.007_bib87","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1038\/s41591-021-01489-1","article-title":"ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials","volume":"27","author":"Calle","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2021.11.007_bib88","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1016\/j.tet.2018.09.008","article-title":"An efficient deprotection method for 5\u2032-[O,O-bis(pivaloyloxymethyl)]-(E)-vinylphosphonate containing oligonucleotides","volume":"74","author":"O\u2019Shea","year":"2018","journal-title":"Tetrahedron"},{"key":"10.1016\/j.ymthe.2021.11.007_bib89","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2-\u0394\u0394CT method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.ymthe.2021.11.007_bib90","series-title":"Lipidomics: Comprehensive Mass Spectrometry of Lipids. Lipidomics: Comprehensive Mass Spectrometry of Lipids","author":"Han","year":"2016"},{"key":"10.1016\/j.ymthe.2021.11.007_bib91","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/978-1-4939-1258-2_13","article-title":"Multidimensional mass spectrometry-based shotgun lipidomics","volume":"1198","author":"Wang","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2021.11.007_bib92","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1002\/rcm.3595","volume":"22","author":"Han","year":"2008","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.ymthe.2021.11.007_bib93","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.1021\/ac900241u","article-title":"Automated lipid identification and quantification by multidimensional mass spectrometry-based shotgun lipidomics","volume":"81","author":"Yang","year":"2009","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ymthe.2021.11.007_bib94","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12864-018-5362-x","article-title":"DEBrowser: interactive differential expression analysis and visualization tool for count data","volume":"20","author":"Kucukural","year":"2019","journal-title":"BMC Genomics"},{"key":"10.1016\/j.ymthe.2021.11.007_bib95","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/s12864-020-6714-x","article-title":"DolphinNext: a distributed data processing platform for high throughput genomics","volume":"21","author":"Yukselen","year":"2020","journal-title":"BMC Genom."},{"key":"10.1016\/j.ymthe.2021.11.007_bib96","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","article-title":"Trimmomatic: a flexible trimmer for Illumina sequence data","volume":"30","author":"Bolger","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ymthe.2021.11.007_bib97","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001621005785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001621005785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T22:44:42Z","timestamp":1716245082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001621005785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":97,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S1525001621005785"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2021.11.007","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An RNAi therapeutic targeting hepatic DGAT2 in a genetically obese mouse model of nonalcoholic steatohepatitis","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2021.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s).","name":"copyright","label":"Copyright"}]}}